ACADIA PHARMACEUTICALS INC - Director's Dealing 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ACADIA PHARMACEUTICALS INC (ACAD)
CIK: 0001070494
Period of Report: 2023-04-29

Reporting Person: Teehan Brendan (EVP, COO, Head of Commercial)

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-04-29	Common Stock	M	1567	$0.00	Acquired	10035	Direct
2023-05-01	Common Stock	S	548	$21.18	Disposed	9487	Direct

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-04-29	Restricted Stock Units	$	M	1567	Disposed		Common Stock (1567)	Direct

F1: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.

F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F3: 50% of the shares subject to the restricted stock units vest on each of April 29, 2022 and April 29, 2023.